Evidence map›Paper›PMID 27941595›Full record

ReviewGenes2016

Achieving HIV-1 Control through RNA-Directed Gene Regulation.

Vera Klemm, Jye Mitchell, Christina Cortez-Jugo, Francesca Cavalieri, Geoff Symonds, Frank Caruso, Anthony Dominic Kelleher, Chantelle Ahlenstiel

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Advances in HIV Gene Therapy.International journal of molecular sciences · 2024
    Review
  2. Review
  3. The Role of Zinc in Antiviral Immunity.Advances in nutrition (Bethesda, Md.) · 2019
    Review
  4. Review
  5. Inhibition of HBV replication by delivering the dual-gene expression vector pHsa-miR16-siRNA in HepG2.2.15 cells.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2017
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Vera KlemmKirby Institute, The University of New South Wales, Sydney, NSW 2052, Australia. vklemm@kirby.unsw.edu.au.
Jye MitchellKirby Institute, The University of New South Wales, Sydney, NSW 2052, Australia. jmitchell@kirby.unsw.edu.au.
Christina Cortez-JugoARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of Melbourne, Parkville, Victoria 3010, Australia. christina.cortez@unimelb.edu.au.
Francesca CavalieriARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of Melbourne, Parkville, Victoria 3010, Australia. francesca.cavalieri@unimelb.edu.au.
Geoff SymondsCalimmune Inc., Darlinghurst, NSW 2011, Australia. geoff.symonds@calimmuneinc.com.
Frank CarusoARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of Melbourne, Parkville, Victoria 3010, Australia. fcaruso@unimelb.edu.au.
Anthony Dominic KelleherKirby Institute, The University of New South Wales, Sydney, NSW 2052, Australia. akelleher@kirby.unsw.edu.au.
Chantelle AhlenstielKirby Institute, The University of New South Wales, Sydney, NSW 2052, Australia. cahlenstiel@kirby.unsw.edu.au.
UNSW Sydney · AUThe University of Melbourne · AUCalimmune (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-1 infection has been transformed by combined anti-retroviral therapy (ART), changing a universally fatal infection into a controllable infection. However, major obstacles for an HIV-1 cure exist. The HIV latent reservoir, which exists in resting CD4+ T cells, is not impacted by ART, and can reactivate when ART is interrupted or ceased. Additionally, multi-drug resistance can arise. One alternate approach to conventional HIV-1 drug treatment that is being explored involves gene therapies utilizing RNA-directed gene regulation. Commonly known as RNA interference (RNAi), short interfering RNA (siRNA) induce gene silencing in conserved biological pathways, which require a high degree of sequence specificity. This review will provide an overview of the silencing pathways, the current RNAi technologies being developed for HIV-1 gene therapy, current clinical trials, and the challenges faced in progressing these treatments into clinical trials.

Indexed as

clinical trialsgene therapyHIV-1RNAitranscriptional gene silencing

Identifiers

PMID27941595
PMCPMC5192495
OpenAlexW2560105603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.